Acute and sub-chronic toxicological evaluation of the herbal product HAD-B1 in Beagle dogs

HAD-B1 is a herbal formula originated from Korean Traditional Medicine that used to treat lung cancer patients. Herein we assessed acute and sub-chronic toxicity of HAD-B1 in beagle dogs. Acute study, 4 weeks dose rate finding (DRF) study and sub chronic toxicity study for 13 weeks were done by oral...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Si-Yeon Song, Hyeok-Joon Chang, Soo-Dam Kim, Eun-Bin Kwag, So-Jung Park, Hwa-Seung Yoo
Formato: article
Lenguaje:EN
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://doaj.org/article/370f48f0f58b4bd6968b2d2324af10b5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:370f48f0f58b4bd6968b2d2324af10b5
record_format dspace
spelling oai:doaj.org-article:370f48f0f58b4bd6968b2d2324af10b52021-11-10T04:27:36ZAcute and sub-chronic toxicological evaluation of the herbal product HAD-B1 in Beagle dogs2214-750010.1016/j.toxrep.2021.11.002https://doaj.org/article/370f48f0f58b4bd6968b2d2324af10b52021-01-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2214750021001864https://doaj.org/toc/2214-7500HAD-B1 is a herbal formula originated from Korean Traditional Medicine that used to treat lung cancer patients. Herein we assessed acute and sub-chronic toxicity of HAD-B1 in beagle dogs. Acute study, 4 weeks dose rate finding (DRF) study and sub chronic toxicity study for 13 weeks were done by oral administration at doses of 0, 500, 1000, and 2000 mg/kg. Neither oral acute toxicity study nor DRF study showed any significant clinical signs, death, or weight changes. Based on that, a sub-chronic study for 13-weeks was performed. As a result, HAD-B1 caused a decrease of mean daily feed consumption in females, infiltration of intestinal inflammatory cells in both sexes, a significant decrease in total cholesterol (TCHO) in females, Kupffer cell hypertrophy/hyperplasia in the liver as well as dilation of the sinusoid. However, there were no significant toxic effects in the treated group compared to the control group. Therefore, the No Observed Adverse Effect Level (NOAEL) of the HAD-B1 is at least 2000 mg/kg/day when administrated orally for 13 consecutive weeks. These results demonstrate that HAD-B1 consumption is relatively non-toxic and safe for clinical usage.Si-Yeon SongHyeok-Joon ChangSoo-Dam KimEun-Bin KwagSo-Jung ParkHwa-Seung YooElsevierarticleAcute toxicitySub-chronic studyLung cancerKorean traditional medicineHerbal productHAD-B1Toxicology. PoisonsRA1190-1270ENToxicology Reports, Vol 8, Iss , Pp 1819-1829 (2021)
institution DOAJ
collection DOAJ
language EN
topic Acute toxicity
Sub-chronic study
Lung cancer
Korean traditional medicine
Herbal product
HAD-B1
Toxicology. Poisons
RA1190-1270
spellingShingle Acute toxicity
Sub-chronic study
Lung cancer
Korean traditional medicine
Herbal product
HAD-B1
Toxicology. Poisons
RA1190-1270
Si-Yeon Song
Hyeok-Joon Chang
Soo-Dam Kim
Eun-Bin Kwag
So-Jung Park
Hwa-Seung Yoo
Acute and sub-chronic toxicological evaluation of the herbal product HAD-B1 in Beagle dogs
description HAD-B1 is a herbal formula originated from Korean Traditional Medicine that used to treat lung cancer patients. Herein we assessed acute and sub-chronic toxicity of HAD-B1 in beagle dogs. Acute study, 4 weeks dose rate finding (DRF) study and sub chronic toxicity study for 13 weeks were done by oral administration at doses of 0, 500, 1000, and 2000 mg/kg. Neither oral acute toxicity study nor DRF study showed any significant clinical signs, death, or weight changes. Based on that, a sub-chronic study for 13-weeks was performed. As a result, HAD-B1 caused a decrease of mean daily feed consumption in females, infiltration of intestinal inflammatory cells in both sexes, a significant decrease in total cholesterol (TCHO) in females, Kupffer cell hypertrophy/hyperplasia in the liver as well as dilation of the sinusoid. However, there were no significant toxic effects in the treated group compared to the control group. Therefore, the No Observed Adverse Effect Level (NOAEL) of the HAD-B1 is at least 2000 mg/kg/day when administrated orally for 13 consecutive weeks. These results demonstrate that HAD-B1 consumption is relatively non-toxic and safe for clinical usage.
format article
author Si-Yeon Song
Hyeok-Joon Chang
Soo-Dam Kim
Eun-Bin Kwag
So-Jung Park
Hwa-Seung Yoo
author_facet Si-Yeon Song
Hyeok-Joon Chang
Soo-Dam Kim
Eun-Bin Kwag
So-Jung Park
Hwa-Seung Yoo
author_sort Si-Yeon Song
title Acute and sub-chronic toxicological evaluation of the herbal product HAD-B1 in Beagle dogs
title_short Acute and sub-chronic toxicological evaluation of the herbal product HAD-B1 in Beagle dogs
title_full Acute and sub-chronic toxicological evaluation of the herbal product HAD-B1 in Beagle dogs
title_fullStr Acute and sub-chronic toxicological evaluation of the herbal product HAD-B1 in Beagle dogs
title_full_unstemmed Acute and sub-chronic toxicological evaluation of the herbal product HAD-B1 in Beagle dogs
title_sort acute and sub-chronic toxicological evaluation of the herbal product had-b1 in beagle dogs
publisher Elsevier
publishDate 2021
url https://doaj.org/article/370f48f0f58b4bd6968b2d2324af10b5
work_keys_str_mv AT siyeonsong acuteandsubchronictoxicologicalevaluationoftheherbalproducthadb1inbeagledogs
AT hyeokjoonchang acuteandsubchronictoxicologicalevaluationoftheherbalproducthadb1inbeagledogs
AT soodamkim acuteandsubchronictoxicologicalevaluationoftheherbalproducthadb1inbeagledogs
AT eunbinkwag acuteandsubchronictoxicologicalevaluationoftheherbalproducthadb1inbeagledogs
AT sojungpark acuteandsubchronictoxicologicalevaluationoftheherbalproducthadb1inbeagledogs
AT hwaseungyoo acuteandsubchronictoxicologicalevaluationoftheherbalproducthadb1inbeagledogs
_version_ 1718440639188697088